The Experience With Health Care of Patients With Inflammatory Arthritis: A Cross-sectional Survey Using the Instrument to Evaluate the Experience of Patients With Chronic Diseases.

Background: Patients' experience with health care is becoming a key component for the provision of a patient-centered health care model. The aim of this study was to assess the experience with health care of patients with inflammatory arthritis and patient- and health care-related factors.
Methods: Patients responded to an anonymous survey provided by their treating clinical teams. The survey comprised the validated 12-item IEXPAC (Instrument to Evaluate the EXperience of PAtients with Chronic diseases) tool and demographic variables and health care-related characteristics that may affect patients' experience.
Results: A total of 359 of 625 surveys were returned (response rate, 57.4%). Overall, patient responses were positive (>60% gave "always/mostly" answers) for statements assessing the interaction between patients and health care professionals or patient self-management following health care professional guidance. However, positive patient responses for items regarding patient interaction with the health care system via the internet or with other patients were less than 13%. Only 25.6% of patients who had been hospitalized reported receiving a follow-up call or visit following discharge. In the bivariate analysis, experience scores were higher (better experience) in men, those seen by fewer specialists or by the same physician, and in patients treated with a fewer number of drugs or with subcutaneous/intravenous drugs. Multivariate analyses identified regular follow-up by the same physician and treatment with subcutaneous/intravenous drugs as variables associated with a better patient experience.
Conclusions: This study identifies areas of care for patients with inflammatory arthritis with the potential to improve patients' experience and highlights the importance of patient-physician relationships and comprehensive patient care.
Competing Interests: L.C.-C., S.F., and Y.M. are full-time employees at Merck Sharp & Dohme Spain. M.L.G.-V. is a consultant to Janssen, Novartis, Bristol, Sanofi, and Celgene; provides expert testimony for Celgene, Novartis, AbbVie, and Pfizer; and receives payments for lectures from Janssen, UCB, AbbVie, Celgene, Novartis, Pfizer, and Lilly; meeting expenses from Pfizer, Sanofi, Lilly, and AbbVie; grants (to her institution) from Janssen and UCB. L.P. is a consultant to UCB and receives payment for lectures from Gebro Pharma, MSD, and Roche. M.J.G. is a consultant to Gilead and Janssen and receives payments for lectures or educational presentations from Gilead, Janssen, MSD, and AbbVie and grant from Janssen. I.M.-J. is a board member of or consultant to AbbVie, Chiesi, FAES Farma, Falk-Pharma, Ferring, Gebro Pharma, Hospira, Janssen, MSD, Otsuka Pharmaceutical, Pfizer, Shire, Takeda, Tillots, and UCB Pharma; and receives payments for lectures from AbbVie, Chiesi, FAES Farma, Falk-Pharma, Ferring, Gebro Pharma, Hospira, Janssen, MSD, Otsuka Pharmaceutical, Pfizer, Shire, Takeda, Tillots, and UCB Pharma. D.O.-B. is a consultant to MSD, Sanofi, Novo Nordisk, Mundipharma, and Menarini. The other authors declare no conflict of interest.
(Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.)